CGON - CG Oncology Inc.
CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
As of Jun 30, 2026: spot at $71.90, ATM IV 120.7%, max pain $60.00, net GEX $3.4M.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $6.35B
- Beta
- 0.31
- 52-Week Range
- 23.65-75.5
- CEO
- Arthur Kuan
- Employees
- 142
- IPO Date
- Jan 25, 2024
- Exchange
- NASDAQ
What CGON Looks Like to Options Traders Today
IV rank of 57.8% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($3.4M) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.036) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The CGON overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked CGON overview questions
- What is CGON?
- CGON is the ticker symbol for CG Oncology Inc., a listed security. CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. Listed on NASDAQ. CGON is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the CGON options snapshot look like today?
- As of Jun 30, 2026, the CGON options snapshot shows spot at $71.90, ATM IV 120.7%, IV rank 57.8%, max pain $60.00, net GEX $3.4M, expected move 34.60%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are CGON's key statistics?
- CG Oncology Inc. (CGON) carries a market capitalization of $6.35B, beta of 0.31 relative to the broader market, 52-week range of 23.65-75.5. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does CGON belong to?
- CG Oncology Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare CGON's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the CGON data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).